Certolizumab Pegol
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1412 publications
Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial.
Journal: EULAR rheumatology open
Published: August 01, 2026
Risk of Adverse Pregnancy Outcomes in Patients with Non-Communicable, Chronic Inflammatory Barrier Diseases Under Systemic Treatment: A Large-Scale Retrospective Cohort Study.
Journal: Biomolecules
Published: June 16, 2026
Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival.
Journal: Dermatology and therapy
Published: May 19, 2026
Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice.
Journal: Journal of the American Academy of Dermatology
Published: May 01, 2026
Comment on "Certolizumab Pegol Reduced Anterior Uveitis Flares Compared With Standard Non-Biologic Treatment: Results From an Overlap Weighting Analysis in High-Risk Patients With Axial Spondyloarthritis".
Journal: International journal of rheumatic diseases
Published: April 23, 2026
The influence of symptom duration on flare risk after biologic DMARD withdrawal in axial spondyloarthritis: a meta-analysis of randomized withdrawal trials.
Journal: Joint bone spine
Published: April 20, 2026
Flare risk after oral glucocorticoid bridging with methotrexate or intra-articular bridging with triple therapy in early rheumatoid arthritis.
Journal: Journal of internal medicine
Published: April 07, 2026
Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators.
Journal: Proceedings (Baylor University. Medical Center)
Published: March 16, 2026
Hearing loss in Behçet's syndrome: prevalence and associated factors in a nationwide cross-sectional analysis.
Journal: Turkish journal of medical sciences
Published: March 13, 2026
Certolizumab Inhibits Radiographic Progression in Patients with Early Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Pooled, Post‑Hoc Analysis of the Phase 3 C‑EARLY and C‑OPERA Trials.
Journal: Joint bone spine
Published: February 24, 2026
Certolizumab inhibits radiographic progression in patients with early rheumatoid arthritis and high rheumatoid factor levels: A pooled, post-hoc analysis of the phase 3 C-EARLY and C-OPERA trials.
Journal: Joint bone spine
Published: February 24, 2026
Last Updated: 09/26/2026